Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Protara confirmed its intent to submit a BLA for TARA-002 in Lymphatic Malformations in the second half of 2027, supported by Breakthrough Therapy designation and ongoing FDA dialogue. The company reported $177.4 million in cash and investments, sufficient to fund operations into 2028, while enrolling patients for the ADVANCED-2 and initiating the ADVANCED-3 trials in the second half of 2026.
Key figures
- Revenue
- 0
- Revenue Yoy
- 0
- Net loss
- $17.8 million
- Cash runway
- into 2028
- Gna expenses
- $6.1 million
- Rnd expenses
- $13.6 million
- Cash position
- $177.4 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.